[go: up one dir, main page]

SG11201911750RA - Low-dose brimonidine combinations and uses thereof - Google Patents

Low-dose brimonidine combinations and uses thereof

Info

Publication number
SG11201911750RA
SG11201911750RA SG11201911750RA SG11201911750RA SG11201911750RA SG 11201911750R A SG11201911750R A SG 11201911750RA SG 11201911750R A SG11201911750R A SG 11201911750RA SG 11201911750R A SG11201911750R A SG 11201911750RA SG 11201911750R A SG11201911750R A SG 11201911750RA
Authority
SG
Singapore
Prior art keywords
combinations
low
brimonidine
dose
dose brimonidine
Prior art date
Application number
SG11201911750RA
Inventor
Gerald Horn
Original Assignee
Eye Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Therapies Llc filed Critical Eye Therapies Llc
Publication of SG11201911750RA publication Critical patent/SG11201911750RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201911750RA 2017-06-08 2018-06-07 Low-dose brimonidine combinations and uses thereof SG11201911750RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516931P 2017-06-08 2017-06-08
US201862621082P 2018-01-24 2018-01-24
PCT/US2018/036440 WO2018226942A1 (en) 2017-06-08 2018-06-07 Low-dose brimonidine combinations and uses thereof

Publications (1)

Publication Number Publication Date
SG11201911750RA true SG11201911750RA (en) 2020-01-30

Family

ID=64562826

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911750RA SG11201911750RA (en) 2017-06-08 2018-06-07 Low-dose brimonidine combinations and uses thereof

Country Status (13)

Country Link
US (2) US20180353504A1 (en)
EP (1) EP3634415A4 (en)
JP (3) JP2020523312A (en)
KR (2) KR20200018580A (en)
CN (2) CN110996954A (en)
AU (2) AU2018279074B2 (en)
BR (1) BR112019025987A2 (en)
CA (1) CA3066398A1 (en)
CL (3) CL2019003572A1 (en)
MX (3) MX2019014748A (en)
MY (1) MY205909A (en)
SG (1) SG11201911750RA (en)
WO (2) WO2018226942A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3818010A4 (en) 2018-07-03 2022-08-17 Fennec Pharmaceuticals, Inc. ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
MX2022014959A (en) 2020-05-27 2023-01-11 Lupin Ltd COMPOSITIONS OF OPHTHALMIC NANOEMULSIONS.
JP2022075651A (en) * 2020-11-06 2022-05-18 千寿製薬株式会社 Liquid formulation for ophthalmology
KR102444571B1 (en) * 2020-11-18 2022-09-19 주식회사태준제약 Ophthalmic composition comprising cetirizine and tocofesolane
WO2024028816A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CN103143022A (en) * 2002-07-30 2013-06-12 奥默罗斯公司 Ophthalmologic irrigation solutions and method
CN100463668C (en) * 2005-05-09 2009-02-25 凌沛学 Reversible thermal gelation aqueous pharmaceutical composition
ITMI20070890A1 (en) * 2007-05-04 2008-11-05 Sifi Spa OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
AU2008344909B2 (en) * 2007-10-16 2013-06-06 Sun Pharma Advanced Research Company Limited Ophthalmic composition comprising a prostaglandin
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) * 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
PT3943069T (en) * 2009-03-17 2025-02-21 Nicox Ophthalmics Inc Ophthalmic formulations of cetirizine and methods of use
EP2408302A4 (en) * 2009-03-17 2012-08-15 Aciex Therapeutics Inc Ophthalmic formulations of ketotifen and methods of use
US20100311688A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US8445526B2 (en) * 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
MX346312B (en) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Ophthalmic treatments.
US20130203813A1 (en) * 2011-05-04 2013-08-08 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
WO2013013143A1 (en) * 2011-07-20 2013-01-24 Allergan, Inc. Fixed dose combination of bimatoprost and brimonidine
US20140194527A1 (en) * 2012-02-29 2014-07-10 Rohto Usa, Inc. Geranylgeranylacetone formulations and retinal delivery thereof
EP2841104A1 (en) * 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
US9833441B2 (en) * 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
WO2015138786A1 (en) * 2014-03-12 2015-09-17 The Trustees Of Columbia University In The City Of New York Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents
CA2998134A1 (en) * 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
US20200197398A1 (en) * 2017-06-08 2020-06-25 Eye Therapies, Llc Netarsudil and low-dose brimonidine combination and uses thereof

Also Published As

Publication number Publication date
EP3634415A1 (en) 2020-04-15
AU2023282222B2 (en) 2025-06-26
AU2023282222A1 (en) 2024-01-04
RU2019144001A (en) 2021-07-09
CN117122600A (en) 2023-11-28
CL2022002566A1 (en) 2023-05-26
CL2019003572A1 (en) 2020-04-24
JP2020523312A (en) 2020-08-06
KR20240090655A (en) 2024-06-21
MX2019014748A (en) 2020-08-03
EP3634415A4 (en) 2021-03-17
WO2019236148A1 (en) 2019-12-12
AU2018279074B2 (en) 2023-12-14
RU2019144001A3 (en) 2022-03-05
AU2018279074A1 (en) 2020-01-16
US20180353504A1 (en) 2018-12-13
MX2022008479A (en) 2022-08-02
US20220233524A1 (en) 2022-07-28
CN110996954A (en) 2020-04-10
CL2022002564A1 (en) 2023-05-26
CA3066398A1 (en) 2018-12-13
JP2024164101A (en) 2024-11-26
KR20200018580A (en) 2020-02-19
WO2018226942A1 (en) 2018-12-13
BR112019025987A2 (en) 2020-06-30
JP2023055823A (en) 2023-04-18
MX2022008478A (en) 2022-08-02
MY205909A (en) 2024-11-20

Similar Documents

Publication Publication Date Title
IL273236A (en) Pyrazolopyrimidinone compounds and uses thereof
IL255577B (en) Tigit-binding agents and uses thereof
IL293377B1 (en) Hsd17b13 variants and uses thereof
IL253433A0 (en) Tnfrsf-binding agents and uses thereof
IL254977B (en) Bioconjugates and uses thereof
SG11201911750RA (en) Low-dose brimonidine combinations and uses thereof
IL292488B1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
IL297057B1 (en) Combinations and uses thereof
SG11202002224XA (en) Composition and uses thereof
IL254241A0 (en) Etv2 and uses thereof
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
IL275211A (en) Fast and partition-resilient blockchains
GB201700404D0 (en) Compounds and composistions
EP3266870A4 (en) Conjugate and use thereof
GB201707279D0 (en) Multiearphones and polyearphones
GB201716745D0 (en) New formulations and uses thereof
IL248576A0 (en) Anti-louse composition and uses thereof